Radiomic features of CECT and SUVmax of dual-tracer PET/CT reveal PD-L1 spatial heterogeneity in PDAC.
Pancreatic ductal adenocarcinoma (PDAC) is characterized by limited responsiveness to immunotherapy due to spatial heterogeneity of PD-L1 expression.
APA
Swain S, Mohakud S, et al. (2026). Radiomic features of CECT and SUVmax of dual-tracer PET/CT reveal PD-L1 spatial heterogeneity in PDAC.. Cancer imaging : the official publication of the International Cancer Imaging Society, 26(1). https://doi.org/10.1186/s40644-025-00960-3
MLA
Swain S, et al.. "Radiomic features of CECT and SUVmax of dual-tracer PET/CT reveal PD-L1 spatial heterogeneity in PDAC.." Cancer imaging : the official publication of the International Cancer Imaging Society, vol. 26, no. 1, 2026.
PMID
41689142
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is characterized by limited responsiveness to immunotherapy due to spatial heterogeneity of PD-L1 expression. Invasive biopsy-based assessments may fail to capture this heterogeneity. This study aims to evaluate non-invasive imaging biomarkers to predict the expression of PD-L1 in 52 PDAC patients using CECT and F-18 FDG PET/CT and Ga-68 FAPI-04 PET/CT imaging. Intensity histogram and Gray Level Co-occurrence Matrix (GLCM) features were extracted from CECT using IBEX software. PD-L1 expression was validated by immunohistochemistry, RT-PCR, and Western blotting. Correlation between PD-L1 expression, SUVmax of F-18 FDG, and FAPI-04 PET/CT and radiomic CECT features were assessed. PDAC tissues demonstrated multimodal intensity histograms with lower histogram peak height correlated with high PD-L1 expression. A moderate positive correlation was observed between PD-L1 expression and FDG uptake (R = 0.36) and a weaker correlation with FAPI uptake (R = 0.19). This Multi-parametric imaging can enhance immunohistochemistry, aiding in patient stratification for immunotherapy and overcoming the limitations of single-site biopsies.
MeSH Terms
Humans; B7-H1 Antigen; Positron Emission Tomography Computed Tomography; Pancreatic Neoplasms; Male; Female; Fluorodeoxyglucose F18; Carcinoma, Pancreatic Ductal; Middle Aged; Aged; Radiopharmaceuticals; Radiomics